Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) were up 5.7% on Monday . The company traded as high as $24.04 and last traded at $23.85. Approximately 562,800 shares were traded during trading, an increase of 131% from the average daily volume of 243,719 shares. The stock had previously closed at $22.56.
A number of analysts have recently issued reports on CNCE shares. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Concert Pharmaceuticals in a research note on Monday, September 18th. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. TheStreet raised Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. Finally, Mizuho began coverage on Concert Pharmaceuticals in a research report on Thursday, October 26th. They set a “buy” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $23.00.
In other Concert Pharmaceuticals news, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the company’s stock in a transaction dated Thursday, October 19th. The shares were acquired at an average cost of $15.84 per share, for a total transaction of $5,257,549.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ryan Lynch sold 3,500 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $14.51, for a total value of $50,785.00. Following the transaction, the insider now owns 9,500 shares in the company, valued at $137,845. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Concert Pharmaceuticals (CNCE) Trading Up 5.7%” was published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/04/concert-pharmaceuticals-cnce-trading-up-5-7.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
What are top analysts saying about Concert Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Concert Pharmaceuticals Inc and related companies.